Skip to content
Buy This GLP
← Research
Evidence

Wegovy Fills After the 2024 Cardiovascular Label and Part D Coverage: Up 136%

After the March 2024 cardiovascular label expansion and Medicare Part D coverage, Wegovy fills rose 136.4% overall and 598.1% through Part D.

Editorial profile: Neil SandersBuy This GLP Editorial Team6 min read
Increase in Wegovy fills after March 2024all payers136.4%Medicare Part D598.1%Wegovy fills increased after coverage expanded.Only for cardiovascular risk, and only with that diagnosis.

The GLP-1 monthly cost guide puts cash prices in context. Coverage can change what a patient pays without changing the published price, so this analysis looks at insurance and access after the label changed.

What changed, and when

Two things happened in March 2024. The FDA added an indication to Wegovy: reducing cardiovascular events in adults with overweight or obesity and established cardiovascular disease. And Medicare Part D began covering it for that indication. [1]

The 2024 coverage change applied to the new cardiovascular indication. Since July 2026, the separate Medicare GLP-1 Bridge has offered certain GLP-1s to eligible beneficiaries for weight management outside the regular Part D benefit.

What happened to volume

National prescription data from September 2023 to September 2024 show total semaglutide use rising, with Wegovy up by 136.4% relative to the period before the change — the largest relative increase of any semaglutide product.

Through Medicare Part D, Wegovy rose by 598.1%. The authors’ regression associated the policy changes with an estimated 592,624 additional fills by September 2024.

Who qualified under the 2024 change

The cardiovascular indication applies to adults with established cardiovascular disease and overweight or obesity. The study’s observation period ended in September 2024, before the GLP-1 Bridge began. If you have insurance through work, the employer coverage guide explains how to check your plan’s criteria for the condition being treated.

What fill counts can tell you

A fill counts a prescription dispensed. A person can fill several prescriptions, so the study does not measure the number of people who started treatment. The guide to absolute treatment effects explains how trials measure events prevented. This study measured pharmacy use by payer and did not report what individual patients paid.

Frequently asked

Did Wegovy get cheaper?
The study measured prescription fills by payer. It did not measure changes in list price or what individual patients paid.
Who does the Medicare coverage apply to?
Adults with overweight or obesity and established cardiovascular disease, for reducing cardiovascular events. The separate Medicare GLP-1 Bridge has its own eligibility criteria for weight management.
How big was the increase?
The study reported a 136.4% increase overall and a 598.1% increase through Medicare Part D, from 4,689 to 32,732 fills in the reported Part D comparison.
Where does 592,624 come from?
A segmented regression estimating how many additional fills the policy change accounts for by September 2024. It is a model's attribution, not a direct count.

Sources

  1. [1] Scannell C, et al. (2026). Changes in Semaglutide Fills Following Expanded FDA and Medicare Policies The American Journal of Managed Care. PMID 42640207

Where to get it

Price the injectable sellers

The desk lists every seller that publishes an injectable figure, with the advertised price struck against the one a buyer is billed.

Open the price desk →

More in Evidence